Next Article in Journal
Production of Hyaluronic Acid by Streptococcus zooepidemicus on Protein Substrates Obtained from Scyliorhinus canicula Discards
Next Article in Special Issue
Metals of Deep Ocean Water Increase the Anti-Adipogenesis Effect of Monascus-Fermented Product via Modulating the Monascin and Ankaflavin Production
Previous Article in Journal
Cell Death Inducing Microbial Protein Phosphatase Inhibitors—Mechanisms of Action
Open AccessArticle

Simultaneous Determination of Fucoxanthin and Its Deacetylated Metabolite Fucoxanthinol in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry

by 1,2,3, 2,*, 2, 1,3, 1, 1,3 and 2
1
Third Institute of Oceanophy Sgratate Oceanic Administration, Xiamen 361005, Fujian, China
2
College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China
3
Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Xiamen 361005, Fujian, China
*
Author to whom correspondence should be addressed.
Academic Editors: Patrizia Russo and Massimo Fini
Mar. Drugs 2015, 13(10), 6521-6536; https://doi.org/10.3390/md13106521
Received: 28 August 2015 / Revised: 28 August 2015 / Accepted: 5 October 2015 / Published: 23 October 2015
(This article belongs to the Special Issue Marine Natural Products that Target Metabolic Disorders)
Fucoxanthin and its deacetylated metabolite fucoxanthinol are two major carotenoids that have been confirmed to possess various pharmacological properties. In the present study, fucoxanthinol was identified as the deacetylated metabolite of fucoxanthin, after intravenous (i.v.) and intragastric gavage (i.g.) administration to rats at doses of 2 and 65 mg/kg, respectively, by liquid chromatography-tandem mass spectrometric (LC-MS/MS) analysis. Next, an accurate and precise LC-MS/MS method was developed to quantitatively determine fucoxanthin and fucoxanthinol in rat plasma. Plasma samples were resolved by LC-MS/MS on a reverse-phase SB-C18 column that was equilibrated and eluted with acetonitrile (A)/aqueous 0.1% formic acid (B; 92/8, v/v) at a flow rate of 0.5 mL/min. Analytes were monitored by multiple-reaction monitoring (MRM) under positive electrospray ionization mode. The precursor/product transitions (m/z) were 659.3→109.0 for fucoxanthin, 617.2→109.0 for fucoxanthinol, and 429.4→313.2 for the internal standard (IS). Calibration curves for fucoxanthin and fucoxanthinol were linear over concentrations ranging from 1.53 to 720 and 1.17 to 600 ng/mL, respectively. The inter- and intraday accuracy and precision were within ±15%. The method was applied successfully in a pharmacokinetic study and the resulting oral fucoxanthin bioavailability calculated. View Full-Text
Keywords: fucoxanthin; fucoxanthinol; metabolite; LC-MS/MS; pharmacokinetics fucoxanthin; fucoxanthinol; metabolite; LC-MS/MS; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Zhang, Y.; Wu, H.; Wen, H.; Fang, H.; Hong, Z.; Yi, R.; Liu, R. Simultaneous Determination of Fucoxanthin and Its Deacetylated Metabolite Fucoxanthinol in Rat Plasma by Liquid Chromatography-Tandem Mass Spectrometry. Mar. Drugs 2015, 13, 6521-6536.

Show more citation formats Show less citations formats

Article Access Map

1
Only visits after 24 November 2015 are recorded.
Mar. Drugs, EISSN 1660-3397, Published by MDPI AG
Back to TopTop